IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy

Diabetes, Obesity & Metabolism
Eden MillerLiana K Billings

Abstract

Basal-bolus therapy is associated with greater treatment burden and lower adherence compared with more simplified regimens. This post hoc analysis studied the difference between insulin degludec/liraglutide (IDegLira) and basal-bolus therapy on number of injections, dose adjustments and patient outcomes in the DUAL VII trial. DUAL VII was a 26-week, open-label trial in which patients with uncontrolled type 2 diabetes who were using metformin and insulin glargine 100 units/mL (20-50 U) were randomized 1:1 to IDegLira (N = 252) or basal-bolus (insulin glargine U100 + insulin aspart ≤4 times/day) (N = 254). This post hoc analysis reports the observed mean number of injections and cumulative dose adjustments during 26 weeks of treatment. Patient-reported outcomes (Treatment-Related Impact Measure - Diabetes [TRIM-D] and Short Form-36 Health Survey version 2 [SF-36v2]) were collected at scheduled visits and change from baseline scores calculated. The clinical benefits (non-inferior HbA1c reductions, weight benefit, less hypoglycaemia) of IDegLira vs basal-bolus therapy were achieved with fewer cumulative dose adjustments (16.6 vs 217.2, respectively) and fewer injections (1 vs ≥3 per day, respectively). Patients treated with IDegLir...Continue Reading

References

Feb 24, 2001·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·J A Hixson-WallaceS A Blakey
Jan 28, 2010·Diabetes Care·Mark PeyrotLuther B Travis
Mar 23, 2011·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Meryl BrodDonald M Bushnell
Jan 25, 2012·Patient Preference and Adherence·Carla Dias BarbosaDiana Rofail
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Aug 13, 2014·Diabetes Care·John B BuseUNKNOWN NN9068-3912 (DUAL-II) Trial Investigators
Jan 3, 2016·Psychoneuroendocrinology·Rozita H AnderbergKarolina P Skibicka
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jul 17, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ronan RousselBruno Detournay
Aug 31, 2016·Patient Preference and Adherence·Kristina Secnik BoyeLuis-Emilio Garcia-Perez
Sep 3, 2016·Diabetic Medicine : a Journal of the British Diabetic Association·H W RodbardUNKNOWN Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators
Jun 13, 2017·The New England Journal of Medicine·Steven P MarsoUNKNOWN DEVOTE Study Group
Oct 21, 2017·Diabetes, Obesity & Metabolism·David Russell-JonesKamlesh Khunti
Apr 11, 2018·Diabetology & Metabolic Syndrome·Rodrigo Oliveira MoreiraRaquel C Lopes Assis Coelho
May 23, 2018·Diabetes Care·UNKNOWN Beyond A1C Writing Group
Jun 27, 2018·BMJ Open Diabetes Research & Care·Russell DrummondBengt-Olov Tengmark

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02420262

Software Mentioned

IDegLira
DEVOTE

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.